Similarly, in individuals with overweight or obesity, the SELECT trial demonstrated a 19% reduction in all-cause death with semaglutide, extending the survival benefit of GLP-1 RAs beyond diabetic populations [8, 23]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.